about
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigenCyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor responseRandomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the data (or lessons learned in medical policy governing clinical research).Critique of the high-dose chemotherapy studies in breast cancer: a positive look at the data.A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.High-dose therapy for breast cancer.International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury.Introduction: the history of arsenic trioxide in cancer therapy.High-dose chemotherapy in breast cancer: the end of the beginning?Randomized trials of high dose chemotherapy for breast cancer.New biology and therapies in soft tissue sarcomas.Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience.Dose intensive therapy in breast cancer.New developments in clinical oncology: the interdependence of bench and bedside.High-dose chemotherapy in solid tumours. A review of published data in selected tumours with a commentary.Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. A case report and brief literature review.Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation.High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.Malignant mesothelioma following treatment for Hodgkin's disease.Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.Adjuvant therapy of sarcomas of soft tissue.Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.Melanoma and soft tissue sarcoma in seven patients.Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.The crisis in clinical cancer research. Third-party insurance and investigational therapy.A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer.High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.The impact of clinical trial protocols on patient care systems.Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.Update on malignant mesothelioma.High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.Primary Kaposi's sarcoma of the lung in an immunocompetent 32-year-old heterosexual white man.Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network Symposium.Specific barriers to the conduct of randomized trials.Designing and Funding Clinical Trials of Novel Therapies
P50
Q28282988-4AD0350E-7F7C-47A1-9F28-61973ECE90D3Q28319878-FA39892E-67ED-498B-8CCB-979235609999Q30696719-57EDA7B6-1B83-4811-961E-F4F07468A9FEQ31447679-FC8EE048-748F-4C8B-B25B-431A03E8836DQ33374884-59155F69-26BF-475C-9978-E734A7CBAAF8Q33453063-E79300C5-C063-4CF5-A2C4-4B172AE32961Q33495223-8928B554-948B-4336-B9BD-5C8CBEA91327Q33541091-CB549FCB-34AE-4EF2-A5EB-B42354B6E11BQ33944990-98A49E25-B6EF-427E-86A7-EB7405448CE1Q34076587-C3027405-70B6-4B6F-9967-3EC9F1BDB3F3Q34183739-B18D9402-61C5-4966-8B9D-49E52D286D73Q34479812-83C86F92-7A7F-47F5-8EB6-C9484BAD30C1Q34545093-17EA6607-9511-42F2-ADAE-F8B74682C33AQ35234868-39F0AC3C-7EAE-469B-B5FC-1DA697A8563BQ35264717-080186F9-80BB-4043-B3EC-D341CDFD085FQ36515879-FA5C9401-ED9F-40E8-95E5-90707E03D943Q36771886-300ACD94-8479-4808-A713-83A8E96063ECQ39543767-176E7C80-3EFC-4BA4-B955-3779FEB30D01Q40751178-433A1529-37D7-4403-82BB-65B49D28DD83Q41016165-F1D3C2B8-635D-443E-A214-89E5DA2449CBQ41017788-1A6773E3-D893-4389-8C8C-9836C9EEEB82Q41218472-A11EC0EC-6368-4858-B5AF-CC51CFCA4BE9Q41621494-B22BDDA8-F3BF-4B4A-B0D1-C99E2F43ED77Q41723648-96562AC3-7617-4C86-93BE-F43FA1F6D05BQ41835446-878AE1B9-F0D0-4444-8D65-17D8075DE24EQ42247914-88D88842-FEB3-4BD2-A7D6-425DF1D9025FQ42540874-C7BA3DD2-B319-4650-8AC0-8593924E593EQ42549226-5920B7E3-8516-4AD7-9F94-A8D79B11F91DQ44208114-84047EC6-6CB8-4778-9B1B-7923BE204D94Q44291819-BE7783E1-0850-4178-819C-871512C1361BQ44499716-E0689EE1-8A7D-405B-862F-43B36F007DCFQ44519656-B36E46B4-D819-413C-89E7-74965DF9D064Q45093060-E5F6E208-DF3F-4179-BB3F-633E4B82F602Q45885192-CC7E32B3-BC9A-411F-B9C1-F2B2AF6FD3E6Q46801743-103C6C6A-C4AF-4951-89D3-FF08B4613778Q48349608-62F24BC5-6598-4150-BD85-362E94ECBAADQ48612825-13DD53E6-126A-49CA-A5DE-8C479873A96CQ50107215-9B368CFF-BA61-4600-92E5-8D08F781F4CEQ52852045-BB6119F9-91D5-493C-9EAD-40C3EDD5065CQ53474210-7115E1C1-49CC-4232-8CE1-0E9A81FC7D8C
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
K Antman
@ast
K Antman
@en
K Antman
@es
K Antman
@nl
type
label
K Antman
@ast
K Antman
@en
K Antman
@es
K Antman
@nl
prefLabel
K Antman
@ast
K Antman
@en
K Antman
@es
K Antman
@nl
P31
P496
0000-0002-1093-8356